您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Luzopeptin A
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Luzopeptin A
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Luzopeptin A图片
CAS NO:75580-37-9
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
Cas No.75580-37-9
别名BBM-928A
化学名Luzopeptin A
Canonical SMILESCC(O[C@@H]1[C@@](N2N=CC1)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C3=NC4=CC=C(OC)C=C4C=C3O)=O)C(N5[C@]([C@@H](OC(C)=O)CC=N5)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C6=NC(C=CC(OC)=C7)=C7C=C6O)=O)C2=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=
分子式C64H78N14O24
分子量1427.4
溶解度Soluble in DMSO;Soluble in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Luzopeptin A is a cyclic depsipeptide antibiotic.

A depsipeptide is a peptide in which one or more of its amide groups are replaced by the corresponding ester, or more generally, is a molecule that has both peptide and ester linkages in proximity in the same amino acid-containing small molecule or chain.

In vitro: Previous study found that luzopeptin A treatment could produce additional DNA bands which were the products of type II biintercalation. The types of restriction fragments involved were identified. Maximal type II biintercalation occurred at a luzopeptin A/DNA range of 0.14 to 0.18, at which more than 50% of the total DNA molecules were involved. Type II products were gradually converted to type I products upon prolonged incubation at 37 degrees, maybe due to the tendency for intermolecular bonds to disrupt. Echinomycin treatment failed to produce type II products, probably because of a DNA-binding affinity weaker than that of luzopeptin A [1].

In vivo: Animal study showed that when administered as a suspension in 0.9% NaCl solution, luzopeptin A demonstrated good activity against i.p. B16 melanoma and i.p. P388 leukemia and weak activity versus i.v. P388, i.p. L1210 leukemia, Lewis lung, and Madison 109 lung carcinomas. In terms of tumor cell kill, luzopeptin A induced net reductions in the body burdens of L1210 and P388 leukemias following single-drug injections but failed to yield net reductions following multiple-injection therapies [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Huang, C. H.,Mirabelli, C.K.,Mong, S., et al. Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Research 43, 2718-2724 (1983).
[2] Rose WC, Schurig JE, Huftalen JB, Bradner WT.  Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A. Cancer Res. 1983 Apr;43(4):1504-10.